Schrödinger Presents SGR-3515 Preclinical Data at 2024 EORTC …
Oct 23, 2024 · New preclinical data on PRMT5-MTA inhibitor program will also be presented. NEW YORK, NY, USA I October 23, 2024 I Schrödinger (Nasdaq: SDGR) today announced new preclinical data on SGR-3515, its investigational Wee1/Myt1 inhibitor, during a poster session at the 36th EORTC-NCI-AACR Symposium (ENA 2024). The data demonstrate that in preclinical models, treatment with SGR-3515 results in ...
ESSENCE Phase 3 trial results demonstrating statistically significant ...
Nov 20, 2024 · The trial achieved both its primary endpoints, with semaglutide 2.4 mg demonstrating statistically significant and superior improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH compared to placebo. 1 Supportive secondary endpoints showed improvements in liver enzymes, including ...
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO …
Dec 11, 2024 · – Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway PASADENA, CA, USA I December 11, 2024 I Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a ...
UCB Presents Encouraging Data on Bepranemab in Early …
Oct 31, 2024 · Results provide first evidence of biological and clinical effect of a mid-domain tau-targeting disease-modifying therapy 1 ; In full study population primary endpoint was not met, however in key secondary endpoints bepranemab slowed cognitive decline and rate of tau accumulation 2; In pre-defined patient subgroups, consistent treatment benefit shown across multiple primary and secondary ...
REGENXBIO Presents Positive Data from the Phase II Study of …
Oct 21, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Combination of Poolbeg and HOOKIPA Pharma Inc.
Jan 3, 2025 · NEW YORK, NY, USA and VIENNA, Austria I January 02, 2025 I The boards of directors (each a “Board”) of HOOKIPA Pharma Inc. (“HOOKIPA”) and Poolbeg Pharma plc (“Poolbeg”) are pleased to announce that they have entered into non-binding discussions for an all-share acquisition by HOOKIPA of Poolbeg (the “Potential Combination”) to create a strong clinical-stage biopharmaceutical ...
Merck Provides Update on KeyVibe and KEYFORM Clinical …
Dec 17, 2024 · RAHWAY, NJ. USA I December 16, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the discontinuation of the clinical development programs for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG-3 antibody.Vibostolimab is being evaluated as an investigational fixed-dose combination with pembrolizumab (KEYTRUDA ®) in the KeyVibe program.
IMFINZI® (durvalumab) granted Priority Review in the US for …
Dec 6, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Pfizer’s IBRANCE® in Combination with Standard-of-Care …
Dec 14, 2024 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …
Capricor Therapeutics Completes Submission of Biologics License ...
Jan 2, 2025 · Custom Report. La Merie Publishing offers the service of preparing customized reports tailored to the needs and specifications of the customer. We conduct scientific & medical literature evaluations for clients of the biopharmaceutical industry within the scope of …